NEW YORK, June 2, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced NeuroVive Pharmaceutical AB (STO: NVP; OTCQX: NEVPF), a leading mitochondrial medicine company, located in Lund, Sweden, has qualified to trade on the OTCQX® Best Market. NeuroVive Pharmaceutical AB upgraded to OTCQX from the Pink® market.
NeuroVive Pharmaceutical AB begins trading today on OTCQX under the symbol "NEVPF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are proud to welcome NeuroVive Pharmaceutical to our family of established, investor-focused U.S. and global companies on OTCQX," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Upgrading will allow NeuroVive to expand its shareholder base and visibility in the U.S. market without incurring the high cost and duplicative regulatory requirements of a U.S. stock exchange listing."
"I am pleased that NeuroVive Pharmaceutical now is trading on the OTCQX Market. The upgrade to OTCQX will increase NeuroVive's visibility among U.S. investors and potential partners in the U.S. market which is important for us," said NeuroVive´s CEO Erik Kinnman. "We have seen an increasing interest in the company from U.S. based entities during recent years and I believe our trading on the OTCQX Market will help us to ensure a strong US presence going forward."
Sanders Ortoli Vaughn-Flam Rosenstadt LLP serves as NeuroVive Pharmaceutical AB's OTCQX Advisor, responsible for providing professional guidance on OTCQX requirements.
NeuroVive Pharmaceutical AB, is a leading mitochondrial medicine company, located in Lund, Sweden. The company's focus is on producing drug candidates that protect the integrity of the mitochondria, and enhance their function in indications with pressing medical need. Research and development is conducted both in-house and in collaboration with leading international partners. Two of NeuroVive's drug candidates - CicloMulsion® and NeuroSTAT® are currently in early phase II trials. CicloMulsion® is being studied for preoperative treatment of acute kidney injury (AKI) coincident with major surgery, and NeuroSTAT® is being studied for treating traumatic brain injury (TBI). NVP019 is also being developed for the potential use in AKI. In addition to the two clinical trials, NeuroVive also possesses two development platforms designed to develop drug candidates for treating ischemic stroke and a range of mitochondrial disorders (especially those that involve dysfunction of mitochondrial respiratory Complex I). NeuroVive was founded by research physicians with the ambition of transforming research results into new treatments in therapeutic areas with unmet medical needs, including serious diseases that could lead to organ damage and unusual diseases where current therapy options are extremely limited.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-neurovive-pharmaceutical-ab-to-otcqx-300278396.html
SOURCE OTC Markets Group Inc.